EMA — authorised 30 June 2025
- Application: EMEA/H/C/006322
- Marketing authorisation holder: Camurus AB
- Local brand name: Oczyesa
- Indication: Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
- Status: approved
The European Medicines Agency (EMA) granted marketing authorisation for Oczyesa (Sandostatin injection) on 30 June 2025. Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues. This authorisation was granted to Camurus AB, the marketing authorisation holder.